“With over 35 years of experience in medicine, biotechnology, academia, business, and emerging technologies, I have had the privilege of working with numerous exceptional professionals. However, Himanshu stands out as ONE OF A KIND! His unparalleled energy, combined with extensive knowledge of the business, life sciences, and medical fields, as well as his strategic approach to advanced technology, make him an exceptional business partner. I collaborated with Himanshu on a daily basis for over 8 months, and I was consistently impressed by his unwavering enthusiasm to helping people. If you require a leader capable of navigating complex and convoluted environments, Himanshu is the ideal candidate. He brings remarkable passion, respect for people, a unique character, and high-caliber professionalism to every conversation and portfolios he undertakes, and I am confident he will achieve extraordinary results in any role. I’ve seen results of Himanshu’s dedication by myself. He is an epitome of the term - KEY PLAYER and I wholeheartedly recommend Himanshu for any endeavor he pursues. ”
About
That belief has guided 25+ years of…
Activity
-
not exactly breaking but oddly precise: president trump threatens to decimate and destroy all areas of iran if they assassinate or attempt to…
not exactly breaking but oddly precise: president trump threatens to decimate and destroy all areas of iran if they assassinate or attempt to…
Liked by Himanshu Jain
-
If pharma wants a truthful AI model strategy, we need to separate capability from deployability. Proprietary frontier models still lead in broad…
If pharma wants a truthful AI model strategy, we need to separate capability from deployability. Proprietary frontier models still lead in broad…
Shared by Himanshu Jain
Experience & Education
Licenses & Certifications
-
-
-
-
Honored Listee
Marquis Who's Who
Issued ExpiresCredential ID 11b62946230744fb9c230d4fdb1607c5eb2174f498074f6b947bb080f507e20a -
-
-
-
-
HIPAA Certified Life Science Consultant
Health Insurance Portability and Accountability Act
-
Publications
-
Improving Integrated Clinical Trial Management Systems through Blockchain
Genetic Engineering and BioTechnology News
See publicationIntegrated eClinical platforms based on technologies such as blockchain will need to offer common features and functions that support multiple processes and allow for shared datasets, so that data only must be entered once—not multiple times for every part of the process.
-
Is Automation An Elixir For Bringing Speed And Efficiency To Clinical Trials Development Processes?
Clinical Informatics News
See publicationAccording to McKinsey & Company, automating 50% to 70% of tasks has resulted in annual run-rate cost efficiencies of 25% to 30%, process-time reductions of 50% to 60% and triple-digit returns on investment (ROI) across different industries. Could clinical trials see that sort of return on investment?
-
Enabling a Single Integrated View of Critical Real-World Data with Analytics as a Service
Pharmaceutical Executive
See publicationOrganizations need a sound foundation to navigate industry challenges and enable intelligent, proactive decision-making — built on components, such as a single, integrated patient, payer and practitioner data repository, to support a wide variety of healthcare applications and analytics. This is where clinical and commercial insights come together to create a more complete view of the patient experience through the use of Advanced Analytics on Real World Data.
-
The Clock is Ticking: How to Speed up Efforts to Meet Traceability Deadlines
Pharma Manufacturing
See publicationUsing Blockchain and IoT to enable serialization to reduce counterfeits, regulatory compliance and product quality assurance
-
Optimising Patient-Centric Services: a Tailored Solution
Journal for Patient Compliance, 1:3 36-40
Patient behaviour – the largest single factor in compliance
and wellness – can be influenced through a suite of patientcentric services (PCS) allowing the design and implementation
of programmes that support better patient outcomes while
reducing healthcare costs. This approach is based on a solid
understanding of factors that influence patient behavior,
and then employing technology and predictive analytics to
change that behaviour. This paper discusses the need for a…Patient behaviour – the largest single factor in compliance
and wellness – can be influenced through a suite of patientcentric services (PCS) allowing the design and implementation
of programmes that support better patient outcomes while
reducing healthcare costs. This approach is based on a solid
understanding of factors that influence patient behavior,
and then employing technology and predictive analytics to
change that behaviour. This paper discusses the need for a
more sophisticated approach to PCS that includes the use of
predictive analytics for risk modelling, and defines medication
adherence, health and wellness programmes, and remote
patient monitoring.Other authorsSee publication -
Regulatory Implications of Technology Platforms for Patient-Centric Service
Regulatory Affairs Professionals Society, Regulatory Focus 16:11 24-34
In this article I discuss the privacy and regulatory considerations associated with various technology platforms used within disease management or patient centric programs including remote monitoring, wearable biosensor, mobile telephony, and other dimensions of multichannel patient centric programs.
Other authorsSee publication -
Reduction of RF emissions from pulsed electrical supply using an active gate control
Chlamers University of Technology
In this paper a method for reducing RF emissions from PWM operated load is investigated. The idea is to use an active gate control in order to obtain smooth transition between upper and lower voltage level. A smooth transition may reduce emissions compared to using a switching with sharp flanks and thus leading to reduced EMI( Electromagnetic Interference)
Other authors -
Honors & Awards
-
AWS Business Outcomes Award for Q3 2021
US AWS West Coast Team
This award is given to exeuctives who deliver business outcomes for customers in specific area of focus.
Test Scores
-
GRE
Score: 332/340
95th Percentile
Languages
-
English
Native or bilingual proficiency
-
Swedish
Limited working proficiency
-
Hindi
Native or bilingual proficiency
-
German
Elementary proficiency
-
Gujarati
Native or bilingual proficiency
Recommendations received
5 people have recommended Himanshu
Join now to viewMore activity by Himanshu
-
In continuation of my AI in Pharma series, the pharma AI debate is often framed as a binary choice i.e should companies standardize on proprietary…
In continuation of my AI in Pharma series, the pharma AI debate is often framed as a binary choice i.e should companies standardize on proprietary…
Shared by Himanshu Jain
-
JUST IN: The U.S. is revoking a license that authorized the sale of Iranian oil, a key aspect of the memorandum of understanding signed between the…
JUST IN: The U.S. is revoking a license that authorized the sale of Iranian oil, a key aspect of the memorandum of understanding signed between the…
Liked by Himanshu Jain
-
In the Part 2 of post on AI infrastructure arms race, the most useful question is no longer, how powerful is the model? It is, what changed in the…
In the Part 2 of post on AI infrastructure arms race, the most useful question is no longer, how powerful is the model? It is, what changed in the…
Shared by Himanshu Jain
-
Anthropic just shipped Claude Sonnet 5 — and on knowledge work it edges out Opus 4.8, its own flagship, at roughly half the price. The benchmark…
Anthropic just shipped Claude Sonnet 5 — and on knowledge work it edges out Opus 4.8, its own flagship, at roughly half the price. The benchmark…
Liked by Himanshu Jain
-
The AI conversation in pharma is becoming less enthusiastic and more useful. The question is shifting from: “What can the model do?” to: “Which R&D…
The AI conversation in pharma is becoming less enthusiastic and more useful. The question is shifting from: “What can the model do?” to: “Which R&D…
Liked by Himanshu Jain
-
In Part 1 of my AI infrastructure in Life Sciences series, we are realizing slowly that AI in Pharma is no longer just a pilot story but an…
In Part 1 of my AI infrastructure in Life Sciences series, we are realizing slowly that AI in Pharma is no longer just a pilot story but an…
Shared by Himanshu Jain
-
In AI drug discovery, compute alone does not translate into drugs. The real challenge is converting models, data, and infrastructure into…
In AI drug discovery, compute alone does not translate into drugs. The real challenge is converting models, data, and infrastructure into…
Liked by Himanshu Jain
-
What's next for AI in genomics, therapeutics, and drug discovery? NVIDIA, Nebius, and J.P. Morgan are bringing together founders, investors…
What's next for AI in genomics, therapeutics, and drug discovery? NVIDIA, Nebius, and J.P. Morgan are bringing together founders, investors…
Liked by Himanshu Jain
-
Clinical trials are essential to transforming scientific discovery into new medicines for patients. Strengthening the U.S. clinical research…
Clinical trials are essential to transforming scientific discovery into new medicines for patients. Strengthening the U.S. clinical research…
Liked by Himanshu Jain
-
BREAKING NEWS: World's FIRST CAR-T Therapy approved for solid tumors. Satri-cel just got approved by China's NMPA. A CAR-T therapy for a gastrci…
BREAKING NEWS: World's FIRST CAR-T Therapy approved for solid tumors. Satri-cel just got approved by China's NMPA. A CAR-T therapy for a gastrci…
Liked by Himanshu Jain
-
Having worked on AI for health for a few years now, there is a quite significant shift happening that I feel will apply to many application domains:…
Having worked on AI for health for a few years now, there is a quite significant shift happening that I feel will apply to many application domains:…
Liked by Himanshu Jain
-
At the cellular level, your body has about forty different ages (according to one of the largest aging studied ever run and published this week) A…
At the cellular level, your body has about forty different ages (according to one of the largest aging studied ever run and published this week) A…
Liked by Himanshu Jain
-
Clinical AI is entering a new phase as we can see Two Nature papers, “Towards Conversational AI for Disease Management” and “Towards Autonomous…
Clinical AI is entering a new phase as we can see Two Nature papers, “Towards Conversational AI for Disease Management” and “Towards Autonomous…
Shared by Himanshu Jain
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Himanshu Jain
2407 others named Himanshu Jain are on LinkedIn
See others named Himanshu Jain